Viracta Therapeutics, Inc.
News
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...\n more…
Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now
Zacks Investment Research Shares of Viracta (VIRX) have been struggling lately and have lost 17.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock...\n more…
Viracta Therapeutics (NASDAQ:VIRX) PT Lowered to $4.00
Ticker Report Viracta Therapeutics (NASDAQ:VIRX - Get Free Report) had its price objective reduced by equities researchers at Royal Bank of Canada from $6.00 to $4.00 in a report issued on Thursday, Benzinga...\n more…
VIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nVIRX stock results show that Viracta Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…
Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today?
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nViracta Therapeutics stock is up on Wednesday alongside as VIRX investors react to its most recent earnings report and business...\n more…